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Introduction 
It is generally accepted that activation of T cells requires 
two distinct signals (Bretscher and Cohn, 1970; Lafferty 
and Gill, 1993). One signal originates from the ligation of 
theTcell receptor(TCR)complexand itscoreceptors(e.g., 
CD4 and CD8). The second signal is dependent on either 
soluble factors such as interleukin-2 (IL-2) or the interac- 
tion of cell surface molecules that provide essential costim- 
ulatory signals complementary to the TCR-mediated 
events (Liu and Linsley, 1992; June et al., 1994). CD28, 
a 80-90 kDa homodimer expressed on the surface of most 
CD4+ and CD8 +Tcells, is a potent costimulatory molecule. 
Ligating CD28 with anti-CD28 monoclonal antibody (MAb) 
or cells expressing the CD28 counterreceptors (i.e., 87-l 
and 87-2) in combination with limited concentrations of 
anti-CD3 or antigen promotes cell cycle progression and 
increases IL-2 production by regulating IL-2 mRNA at both 
the level of transcription and translation (June et al., 1994; 
Harding et al., 1992; Jenkins et al., 1991a, 1991b; Gimmi 
et al., 1991; Reiser et al., 1992; Lenschow et al., 1992; 
Linsleyetal., 1992b;Fraseretal., 1991;Milleretal., 1989). 
Thus, the two-signal model for T cell activation can be 
viewed as the ability of CD28 to deliver biochemical signals 
that function in synergy with TCR-mediated signaling to 
initiate and maintain T cell responses. 
Interest in CDP&mediated costimulation has been fu- 
eled by theobservations that, under certain conditions, the 
blockade of CD28 signaling can result in T cell tolerance 
(Miller et al., 1989; Jenkins et al., 1991a; Schwartz et al., 
1989; Lenschow et al., 1992; Finck et al., 1994; Lin et al., 
1993). For instance, stimulation of Thl T cell clones in the 
presence of F(ab) fragments of anti-CD28 MAb, CTLA-419 
(a soluble CD28 homolog that blocks CD28-B7 interac- 
tions[Linsleyet al., 1991; Harperet al., 1991 a])orcostimu- 
lation-deficient targets inhibits the proliferation of T cell 
clones, blocks IL-2 production, and causes cells to be- 
come anergic (June et al., 1994; Jenkins et al., 1991a; 
Schwartz et al., 1989). These anergic T cells can be res- 
cued from this nonfunctional state by the addition of exog- 
enous IL-2, or by CD28-mediated costimulation (Jenkins 
et al., 1991a; Schwartz et al., 1989). Similarly, in vivo treat- 
ment of mice with CD28 antagonists suppresses humoral 
responses (Linsley et al., 1992b), delays allograft and 
blocks xenograft rejection (Linsley et al., 1992b; Lenschow 
et al., 1992; Lin et al., 1993) and inhibits the progression 
of autoimmune disease (Linsley et al., 1992b; Lenschow 
et al., 1992, 1995; Lin et al., 1993; Finck et al., 1994; 
Perrin et al., 1995). Thus, the control of CD28-mediated 
costimulation may provide a unique site of regulation of 
T cell activation in vitro and in vivo. 
Recent findings indicate that the regulation of costimula- 
tion mediated by the CD2EB7 system is far more complex 
than previously appreciated. First, although CDP&medi- 
ated costimulation is necessary to prevent the induction 
of anergy in Thl T cell clones, the primary effect of CD28- 
mediated costimulation of resting T cells is to promote late 
cell cycle progression by maximizing IL-2 production and 
regulating programmed cell death. CD28 blockade of pri- 
mary T cell activation does not induce anergy, as has been 
found with Thl clones. Second, at least two molecules, 
87-l and 87-2, can function as costimulatory ligands for 
CD28. However, 87-2 appears to be the dominant co- 
stimulatory ligand during primary immune responses, 
whereas 87-1, which is up-regulated later in immune re- 
sponses, may be critical in prolonging primary T cell re- 
sponses or costimulating secondary T cell responses. 
Third, the CD28 homolog, CTLA-4, functions to down- 
regulate immunity by binding with high affinity to B7family 
members. And finally, under certain conditions, T cells 
can be activated in a CD28-independent manner. T cell 
activation can be CD28 independent as a result of engage- 
ment of alternative costimulatory pathways or high potency 
TCR ligation. This review will summarize current studies 
that address the complexity of CD28 costimulation and 
propose a model for CD28 costimulation based on the 
premise that CD28 ligation acts synergistically with TCR 
ligation to maximize T cell signaling, promote cell differen- 
tiation/expansion, and, as a consequence, regulate the 
balance of inflammatorylhumoral (Thl/Th2) responses 
during an immune reaction. 
Multiple 87 Family Members Differentially Regulate 
Immune Responses 
The first ligand identified for CD28 was 87-l (CD80) (re- 
viewed by June et al., 1994; Liu and Linsley, 1992). 87-l 
is normally expressed at low levels on “professional” anti- 
gen-presenting cells (APCs), such as dendritic cells, mac- 
rophages, and thymic epithelial cells. However, it is up- 
regulated on these APCs as well as on B lymphocytes 
following activation by soluble factors (e.g., endotoxin and 
cytokines) or ligation of cell surface molecules (e.g., class 
II and CD40) (Lenschow et al., 1993; Nabavi et al., 1992; 
de Boer et al., 1993). Initial studies suggested that 87-l 
was the CD28 ligand that mediated costimulation. In vitro 
studies using 87-l transfectants demonstrated that 87-l 
could interact with CD28 to costimulate both antigen- and 
mitogen-driven T cell proliferation and IL-2 production 
(Reiser et al., 1992; Wu et al., 1993). In subsequent in 
vivo studies, viral glycoprotein-specific class l-restricted 
TCR transgenic mice expressing the viral glycoprotein se- 
lectively on 8 cells of the islets of Langerhans were shown 
to remain normoglycemic unless the double-transgenic 
mice were crossed with a third transgenic animal express- 
ing B7-1 on the 3 cells. These studies suggested that ex- 
pression of B7-1 on 8 cells provided a sufficient costimula- 
tory signal to promote the breakdown of tolerance and 
the development of diabetes under conditions that were 
Immunity 
556 
otherwise nonpathogenic (Harlan et al., 1994; Guerder et 
al., 1994). 
It has been much more difficult to demonstrate that 67-l 
can function on normal APCs to costimulate T cells. Anti- 
87-l MAbs have minimal effect on primary mixed lympho- 
cyte reactions and B7-l-deficient mice respond normally 
to nominal antigens in vitro and in vivo (Lenschow et al., 
1993; Freeman et al., 1993b). These observations led to 
the prediction and ultimate discovery of a second CD28 
ligand, 67-2. Unlike B7-l,B7-2 is constitutively expressed 
on dendritic cells and macrophages and is rapidly up 
regulated on B cells following activation by cross-linking 
of the immunoglobulin receptor or the addition of a variety 
ofcytokines(Lenschowet al., 1993; Hathcocket al., 1994). 
Both the mouse and human 87-2 (CD88) glycoproteins 
have been shown to have sequence similarity to 87-1, 
and bind CD28 as well as CTLA4 (Freeman et al., 1993a, 
1993c; Azuma et al., 1993). Transfectants expressing the 
87-2 molecule provide effective costimulation of Thl T 
cell clones and primary T cells. In contrast with anti-B7-1 
MAbs, anti-B7-2 MAbs are potent inhibitors of T cell prolif- 
eration and cytokine production in vitro (Lenschow et al., 
1993; Wu et al., 1993; Chen et al., 1994). In fact, in in 
vivo studies, 87-2 has been shown to be the major CD28 
costimulatory ligand active in a clonal expansion system 
in which antigen-specific cells can be directly quantitated 
(Kearney et al., 1994) in the development of diabetes in 
NOD mice (Lenschow et al., 1995), and in the stimulation 
of T-dependent antibody responses (Hathcock et al., 
7994). However, in both the adoptive transfer, clonal 
expansion model, and the humoral response studies, anti- 
87-2 plus anti-B7-1 was needed to block the immune re- 
sponse completely. Collectively, these results indicate 
that 87-2, not B7-1, is the primary costimulatory molecule 
responsible for initiating T cell responses and providing 
cognate help for B cells. 
However, other recent studies suggest that, under cer- 
tain conditions, 87-l may play a more dominant costimula- 
tory function. B7-l-transfected tumors are potent stimula- 
tors of primary T cell responses both in vitro and in vivo. In 
a number of tumor systems, 87-l may, in fact, costimulate 
tumor immunity better than 87-2. In addition, anti-B7-1 
MAbs have been shown to block experimental autoim- 
mune encephalitis (EAE) (Kuchroo et al., 1995). Interest- 
ingly, in the NOD model, anti-B7-1 MAb therapy exacer- 
bates disease (Lenschow et al., 1995). However, this 
increased inflammatory response appears to be a conse- 
quence of activating properties of the MAbs, not their 
blockade of 87-l binding to CD28. These studies empha- 
size that MAb therapy may alter immune function either 
by blocking costimulation during an inflammatory re- 
sponse or by directly signaling B7-l-expressing cells. 
Overall, these findings emphasize two important as- 
pects of 87-2 and 87-l biology. First, there may be intrinsic 
differences in the binding and signaling capacity of these 
two molecules. When expressed at equivalent levels (as 
when transfectants are used or in inflammatory lesions 
such as those that develop in EAE), 87-l appears more 
potent in stimulating inflammatory responses. However, 
in the in vivo “natural” setting, 87-2 appears to dominate 
both inflammatory and humoral responses, most likely ow- 
ing to differences in the cellular distribution and kinetics 
of expression of these CD28 counterreceptors. In this re- 
gard, constitutive expression of 87-l on B cells results in 
decreased humoral responses in vivo (Sethna et al., 1994) 
and 87-2 transfectants preferentially activate The-type cy- 
tokines in human T cells, whereas 87-l transfectants 
skewed responses towards the production of Thl-type cy- 
tokines (Freeman et al., 1995). Finally, while MAbs to 87-l 
inhibit the development of murine EAE, anti-B7-2 MAb 
therapy made the disease worse (Kuchroo et al., 1995). 
Since EAE is thought to be mediated by Thl-type cyto- 
kines, these results are consistent with the notion that the 
anti-B7-1 MAbs block the development of Thl T cells and 
consequently the progression of disease, while anti-B7-2 
MAbs block the development of protective Th2 T cell re- 
sponses resulting in the increased disease severity. In 
fact, recent molecular analyses have shown that 87-2 and 
B7-1 molecules bind distinct regions of the CTLA4 mole- 
cule and have distinct kinetics of binding to CTLA4 and, 
most likely, CD28 molecules (Linsley et al., 1994). Such 
differential binding may have unique signaling properties 
that affect T cell activation and subsequent Thl /Th2 devel- 
opment. 
There are, however, several observations that do not fit 
with this interpretation of the results. Anti-B7-2 MAbs are 
very efficient at blocking delayed-type hypersensitivity and 
humoral responses; anti-B7-2 MAbs block the develop 
ment of diabetes in NOD mice (a Thldependent autoim- 
mune disease): and under some circumstances, both 87-l 
and 87-2 transfectants induce potent antitumor responses 
in vivo (Chen et al., 1992, 1994). These results suggest 
a potential role for B7-2-mediated activation of Thl re- 
sponses. Moreover, Lanier et al. (1995) have reported that 
stimulation of human T cells with 87-2 transfectants can 
induce similar levels of Thl -type and ThP-type cytokines. 
Thus, it is likely that factors, in addition to the intrinsic 
binding activity of 87-l and 87-2 for CD28, may be influ- 
encing the in vitro and in vivo results observed. 
One explanation for the paradoxical roles of B7-1 and 
87-2 may relate to significant variability in the relative 
strength of the TCR-mediated signals following exposure 
to antigen in the different systems. For instance, the rela- 
tive differences in 87-l and 87-2 potency in the tumor 
transfection system may depend on the antigenicity of the 
tumor. The presence of the potent costimulatory molecule 
87-2 may deliver adistinct signal to theTcells, hyperstimu- 
late the immune response to shut down T cells either di- 
rectly, perhaps through its interaction with CTlA-4, or in- 
crease the potency of the T cell signals to promote Th2 
responses that inhibit tumor immunity. 
Where Does CTLA-4 Fit In? 
An additional level of complication in the regulation of the 
CD28-87 pathway is the existence of a CD28 homolog, 
CTLA-4 (Harper et al., 1991 b). This T cell-specific marker 
is expressed only on activated T cells, including both the 
CD4+ and CD8+ subsets (Walunas et al., 1994). Further- 
more, CTLA4lg (a fusion protein comprised of the CTLA4 
extracellular domain and the Fc portion of the human im- 
munoglobulin Gl constant region) binds to B7-l-and B7-2- 
transfected CHO cells with a 18- to 26fold higher affinity 
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for 87-l and 87-2 than does CD28 (Linsley et al., 1991). 
Studies of CTLA4 regulation have shown that maximal 
cell surface expression depends on a CD28-mediated sig- 
nal that can not be fully overcome by the addition of IL-2 
(Walunas et al., 1994). However, the function of CTLA4 
has been a source of some controversy. Initial studies 
suggested that antihuman CTU4 antibodies could pro- 
vide an enhanced costimulatory signal to activated T cells, 
and that stimulation through CD28 and CTLA4 was syner- 
gistic (Linsley et al., 1992a). These conclusions were 
based on studies in which anti-CTlA-4 antibodies added 
to activated T cell populations resulted in increased prolif- 
erative responses and IL-2 production. However, other re- 
ports suggest that the signal delivered to the Tcell by CD28 
and CTLA4 may be fundamentally different (Walunas et 
al., 1994). For example, F(ab) fragments of antiCTlA-4 
antibodies can actually augment T cell proliferation in an 
allogeneic mixed lymphocyte reaction, in contrast with 
F(ab) fragments of antiCD28, which severely inhibit prolif- 
erative responses (Walunas et al., 1994). These results 
suggested that the MAbs were, indeed, blocking the bind- 
ing of CTLA4 to its natural ligand; thus, preventing trans- 
duction of a down-regulatory signal normally delivered via 
the CTLA4 molecule. In fact, anti-CTLA-4 antibodies can 
induce programmed cell death in activated human T cell 
populations (Gribben et al., 1995). Thus, it would appear 
that in contrast with CD28, CTLA4 is an important T cell 
down-regulatory molecule. Since CTLA4 has a much 
higher affinity for both the 87-l and 87-2 ligands, control 
of the immune response may depend on a competition 
between CD28 and CTLA4 on the activated Tcell for 87-l 
and 87-2 on the APCs. The interaction of CTLA4 with 
these ligands may either signal the T cell to stop proliferat- 
ing and die or deprive the cells of necessary positive sig- 
nals delivered via the CD28 molecule. 
Is CD28 Really Required for Primary 
T Cell Activation? 
In spite of the increasing evidence that CD28 costimulation 
is required for effective T cell activation, it remains unclear 
whether the signals that are delivered by CD28 can be 
replaced by other costimulatory cell surface molecules or 
by supraoptimal TCR-mediated signaling. Many studies 
have noted that the blockade of CDPB-mediated signals 
always results in a residual, albeit significantly reduced, 
primary T cell response. The addition of CD28 antagonists 
such as CTLA4lg and anti-B7 MAbs does not fully inhibit 
primary T cell proliferation or IL-2 production (Chen et al., 
1994; Green et al., 1994; Lenschow et al., 1993). Further- 
more, T cells isolated from CD28deficient mice can re- 
spond, although less efficiently, to alloantigen, nominal 
antigen, and anti-CD3 MAbs (Lenschow et al., 1993). In 
fact, these animals can clear some viral infections (Shahi- 
nian et al., 1993) and reject foreign tissue grafts. Finally, 
unlike the results observed with Thl T cell clones, block- 
ade of CD28B7 interactions on primary T cells does not 
result in clonal anergy. In in vivo studies, the secondary 
T cell response in CD28 antagonist-treated animals iS 
equal or greater than control animals (Ronchese et al., 
1994). These results suggest a supportive but not essen- 
tial role for CD28 signaling in primary T cell responses. 
There are several possible explanations for the ability 
of primaly T cells to bypass the requirement for CD28 
mediated costimulation. First, other costimulatory mole- 
cules may substitute or complement CD28-B7 interac- 
tions, especially in CD28deficient systems. Molecules 
such as CD44 (Naujokas et al., 1993), CD43 (Sperling et 
al., 1995) or the ligand for heat-stable antigens on T cells 
(Liu et al., 1992), have been implicated in this regard. Sec- 
ond, it is possible that costimulation-independent T cell 
activation is exhibited under circumstances of supraopti- 
mal antigen presentation or TCR occupancy. For instance, 
purified CD28deficient T cells could be stimulated with 
anti-CD3 but required about 1 g-fold more antibody to ob- 
tain an equivalent response (Green et al., 1994). Finally, 
the major role of CD28-B7 signaling may be to extend 
the T cell response during an immune reaction. Recent 
studies have shown that CD28-Bir-mediated signaling 
does not affect initial T cell proliferation (at 24-48 hr) but 
rather is critical for sustaining cell expansion at later 
stages of the proliferative response (Green et al., 1994). 
The attenuation of the proliferative response following 
CD28 blockade is manifested as increased T cell death 
(apoptosis) late in culture that cannot be fully reversed by 
the addition of IL-2. Thus, although CD28-B7 interactions 
can clearly facilitate the initiation and progression of T cell 
responses, the requirement for CD28 ligation may not be 
obligatory for primary T cell activation but essential for 
clonal expansion in vitro and perhaps in vivo. 
A Model 
Based on these and other observations, I would suggest 
a model that integrates many of the observations related 
to TCR ligation, CD28 costimulation, and ThlmP biology 
(Figure 1). Liew and Parish (1974) first suggested that the 
strength of TCR engagement by antigen might regulate 
c 
HIGH 














TCR LIGAND DENSITY/AFFINITY 
Figure 1. An Avidity Model for T Cell Coetimulation 
A model is preeented to explain some of the essential obsanratbns 
in CD28-87 immunobbbgy. The immune rwponee is divided into 
four parts depending on the degree of coetimulatbn and TCR ligatbn. 
The model predicts that varying the levsks and CD28-87 partidpante 
during an immune reporse alters the dlfferentlatbn, cetl cycle ptogree- 
sion, and clonal expansion of the reepondlng lymphocytes. 
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immune responses. In these early studies, treatment of 
animal8 with high antigen doses led to a strong antibody 
response, whereas low antigen dO8e8 promoted delayed- 
type hypersensitivity responses. More recently, TCR 
transgenic mice have been used to show that high dose8 
of peptides promote ThP-type cytokine production (IL+, 
whereas low doses of antigens promote Thl-type cyto- 
kines including interferon?. Thus, the strength of T cell 
signaling can affect dramatically the balance of Thl/lhP 
subsets. This strength-of-signal hypothesis may explain 
Some of the observation8 in the CD28-B7 system. It is 
already evident that a variety of factors, including the na- 
ture of the APC expressing the 87 molecules, the affinity 
of the 87 molecules for CD28 or CTLA-4, and the level 
of 87-l and 87-2 expression, may result in significantly 
different signals being delivered to the T cells. Thus, the 
combined effect8 of CD28 costimulation with TM-major 
histocompatibility complexlAg ligation can have distinct 
outcomes depending on antigen dose, APC function, cy- 
tokine milieu, and level of costimulation. The following sce- 
nario8 would be predicted by the following model. 
Under condition8 of low antigen density, CD28 ligation 
is essential, since anti-B7 MAbs and CTLA4g therapy 
or genetic disruption of the CD28 expression result8 in a 
diminished ability to generate a productive primary T cell 
response and severely suppresses T-dependent humoral 
responses. Under these perhaps physiological conditions, 
stimulation of primary T cell responses is largely depen- 
dent on B79-mediated costimulation. At early timepoints 
in the immune response 87-2 is expressed constitutively 
on dendritic cells and functions to regulate both Thl and 
Th2 responses. 
As the immune response progresses, both 87-l and 
87-2 are up-regulated on a variety of APCs, resulting in 
increased costimulatory signalsand an increased strength 
of signal that promotes T cell expansion and cytokine pro- 
duction and may skew the T cell response towards the 
Th2 phenotype. Any reagent or situation that reduces co- 
stimulation during this ongoing response (such as treat- 
ment with anti-B7 MAbs) reduces the strength of signal, 
thus promoting Thl responses. For instance, blockade of 
costimulatory signals provided by 87-2 in the EAE model 
might exacerbate disease by reducing costimulation; thus, 
fostering the stimulation of the default Thl phenotype. 
Under maximal antigen density, such a8 might occur 
during a highly virulent infection or strong transplant rejec- 
tion response, different effects may be seen, depending on 
the degree of costimulation. Under some circumstances, 
CD28 signaling may be bypassed totally due to the high 
T cell receptor occupancy. In fact, in vivo, CD28deficient 
mice can reject allogeneic skin and xenogeneic islet grafts 
normally, respond to high doses of keyhole limpet hemocy- 
anin antigen in an assay of secondary T cell responses 
and mediate potent antiviral responses. Thus, high TCR 
signaling leads to an overall strength of signal that can 
overcome the requirement for CD28 costimulation. How- 
ever, the resulting response is largely inflammatory, con- 
sistent with a relatively reduced CD28dependency of Thl 
responses. Consistent with this idea is the observation 
that immunization of CDPBdeficient mice result8 in the 
activation of T cells but not antibodies. The lack of the 
humoral component may reflect either an insufficient sig- 
nal for Th2 response8 or lack of cooperation between T 
and B cells due to inefficient cell-ceil interactions. The 
addition of some non-CD28-mediated costimulation may 
then promote Th2 responses as illustrated in Figure 1. 
Finally, high level8 of costimulation coupled with high 
TCR occupancy may, in fact, down-regulate immune ie- 
sponses. This effect may occur due to the extensive signal- 
ing via the TCR and CD28 a8 ha8 been suggested as an 
explanation for high zone tolerance or clonal exhaustion. 
Alternatively, the hyperstimulation may substantially up 
regulate CTLA-4 on the activated T cells. The ligation of 
CTLA-4 has been shown to down-regulate immune re- 
sponses. Thus, CTLAWB7 interactions may further am- 
plify the suppression observation under these conditions. 
Thus, in summary, the strengthef-signal hypothesis 
may account for many of the result8 observed in both in 
vitro and in vivo model8 of CD28 costimulation. However, 
a number of unresolved issues remain, including the need 
for a better understanding of the role of 87-l and 87-2 in 
regulating Thl/Th2 responses; the relative contribution of 
these costimulatory ligands directly versus the APCs on 
which they are expressed; and the potential regulatory 
role of signaling events that may be mediated by 87-l or 
87-2 into the APCs or activated T cells themselves. A bet- 
ter understanding of the complicated regulation of the 
CD28-87 pathway will have important implications for us- 
ing CD28-B7 antagonists in transplantation and autoim- 
mune settings and may help to understand T cell lineage 
commitment8 and the degree to which costimulatoty mole- 
cules participate in that decision making process. 
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